INNOVENT BIOLOGICS, INC. 1801 2018 12 31 2018 12 31 2017 12 31 2018 12 31 1 1,481.7 2017 12 31635.7 846.0 2018 12 31 103.3 2017 12 31 82.92018 12 31 1 12. 1
2018 12 31609.8 1,221.72017 12 31 611.9 Incyte Biosciences International Sàrl Incyte Incyte CorporationINCY 2017 12 318.3 127.72018 12 31136.0 2019 2018 12 31 5,156.9 5,873.02017 12 31 716.1 4,338 2018 10 31 r/r chl PD-1 NMPA GMP r/r chl 2
IBI-305 IBI-305 IBI-305 IBI-303 NDA NMPA pemigatinib FGFR1/2/3 itacitinib JAK1 parsaclisib PI3KδIncyte 20 HCMHCM 3
2011 20IBI-308 PD-1r/r chlnmpa IBI-305 IBI-301 IBI- 303 20 IBI-305 IBI-303 NDA NMPA IBI-301 IBI-306PCSK9 IBI-310CTLA4 IBI-101 OX40 IBI-188CD47IBI-101 OX40 IBI-188CD47IBI-318PD-1 IND IBI-307RANKL IBI-110LAG3 IBI-315her2 PD-1IBI-322CD47PD-L1 GLP IND IBI-375 pemigatinib FGFR IBI-376 parsaclisib PI3Kδ IBI-377 itacitinib JAK1 IncyteIND 4
IND r/r 1L 2L 2L (IBI-308) PD-1 NSCLC 2L1L 2LNSCLC 1L 2 NSCLC r/r NK/T2L ESCC 1L 2018 12 24 IBI303 TNF-alpha 2 2018 11 IBI305 VEGF-A r/rcrc 2 2019 1 IBI301 CD20 2 2019 Incyte IBI-377 (Itacitinib) JAK1 Incyte IBI-376 (Parsaclisib) PI3K delta NHL Incyte IBI-375 (Pemiga) tinib FGFR1/2/3 IBI-306 PCSK9 CV IND 2017 9 8 IBI-310 1 CTLA-4 IND 2018 2 13 IBI-101 OX40 IND 2018 6 15 IBI-188 CD47 B IND 2018 8 22 IBI-318 PD-1 3 IND 2019 2 2 IBI-302 VEGF AMD IND 2016 12 9 IBI-307 RANKL IND 2018 6 15 IBI-110 LAG-3 NSCLC mbrca IBI-939 TIGIT IBI-319 PD-1 3 IBI-322 PD-L1/CD47 PD-L1/CD47M1 IBI-315 PD-1/HER2 Her2 + mbrcansclc IBI-323 LAG-3/PD-L1 PD-L1+ 1L = 2L = AMD = CV = ESCC = mbrca = NHL = NK = NSCLC = r/r = (1) IBI-310 NMPAIBI-310 (2) (IBI-308)(IBI-301) (3) IBI-318 IBI-319 5
IND Incyte Incyte Ib II IBI-188 CD47IaIBI-101 OX40FDAIND 1. 2018 11 13IBI-303 NDA NMPA IBI-303TNF- IBI-303 2018 11 13 2018 11 2018 11 29 2018 12 13IBI-305 IBI-305 IBI-305 VEGF 2018 12 13 2018 12 16 Incyte CorporationINCY Incyte Incyte Incytepemigatinib FGFR1/2/3 itacitinib JAK1 parsaclisib PI3Kδ Incyte 40 2018 12 17 6
2018 12 24 PD-1 NMPA r/r chl 2018 12 27 2018 12 29 NMPAGMP 2018 12 10IBI-301 IBI-303 IBI-305 IBI-3012014 IBI-301 2. 2019 1 2 (ORIENT-15) 2019 1 2 2019 1 7 r/r chl ORIENT-1 2019 1 7 2019 1 14IBI-188CD47 2019 1 14 2019 1 17 (ORIENT-16) 2019 1 17 2019 1 29NMPA IBI-305 NDA 2019 1 29 2019 2PD-1 IBI-318NMPA 2019 2 7 2019 2 13OX40 IBI-101 2019 2 13 7
2019 2 IBI-305 (HDAC) I 1 2 3IIb10 2019 2 18 2019 2 22 2019 2 22 2019 2 28(ORIENT-32) IBI-305 2019 2 28 3,000 21,000 2019 3. NDA IBI-305 IBI-303 NDA 2019NMPAIBI-301 NDA 3,000 8
2018 12 31 2017 12 31 12 31 2018 2017 9,477 18,538 93,795 64,406 (4,272,090) (42,079) (1,221,687) (611,922) (220,315) (79,490) (136,006) (8,278) (57,187) (68,969) (57,225) (5,872,982) (716,050) (1,481,694) (635,742) 1. 2018 12 31103.3 2017 12 31 82.9 5,873.02017 12 31 716.1 2018 12 31 1,481.7 2017 12 31635.7 846.0 2018 12 31 1,221.72017 12 31 611.9 2018 12 31 220.32017 12 31 79.52018 12 31 136.02017 12 31 8.3 2. 2018 12 31 9.5 2018 2017 18.5 2017 10.0 9.049% 9
3. (i) (ii) 2018 12 312017 12 31 64.429.446%93.8 E 4. (i) (ii) (iii)(iv) 2018 12 31 2017 12 3142.14,230.0 4,272.1 2018 12 31 4,338.0 2017 12 31 4,287.0 2019 5. 10
12 31 2018 2017 406,668 215,479 191,189 89 228,038 168,934 59,104 35 154,254 84,495 69,759 83 60,326 59,723 603 1 292,727 40,731 251,996 619 79,674 42,560 37,114 87 1,221,687 611,922 609,765 100 2018 12 312017 12 31 611.9609.8100%1,221.7 (i) (ii) Incyte 271 6. 2018 12 312017 12 31 79.5140.8177%220.3 11
7. 2018 12 31 2017 12 318.3127.7 136.0 2019 8. 2018 12 31 2018 10 31 57.2 9. 2018 12 312017 12 31 57.211.821%69.0 2015 3 IBI-301 2018 12 31 74.2 2017 12 31 24.3 11% 2018 12 31 43.92017 12 31 32.3 10. 20182017 12 31 12
11. 2017 12 31716.1 5,156.92018 12 315,873.0 12. 12 31 2018 2017 (5,872,982) (716,050) 4,338,044 51,013 53,244 29,295 1,481,694 635,742 13
12 31 2018 2017 4,686,261 1,445,755 1,426,316 1,011,461 6,112,577 2,457,216 670,321 163,276 1,247,842 3,916,068 1,918,163 4,079,344 4,015,940 1,282,479 13. 2018 12 31 2017 12 31 183.84,524.8E 2018 12 314,686.3 4,525.4 160.9 2018 12 31670.3 42.8 17.0 600.5 10.0 2018 12 31 1282017 12 31 15 14
14. 12 31 2018 2017 (1) 7.0 8.9 (2) 6.9 8.5 (3) NM (4) NM (5) (1) (2) (3) 100% (4) 2018 12 31 (5) 2017 12 31 15. 2018 12 31 16. 2018 12 31 17. 2018 12 31 611.7 54.1 0.5 18. 2018 12 31 15
19. 2018 12 31 2018 12 31 2018 12 31 20. 2018 12 319592018 12 31 492 51.3 121 12.6 264 27.5 82 8.6 959 100.0 2018 12 31 371.2 2017 12 31 135.8 2018 2018 10 18D. 16
2018 12 31 2019 6 13 2019 6 10 2019 6 13 2019 6 6 183 17 1712-1716 2011 4 28 2018 10 31 1. 2018 10 312018 12 31 14 A.1.1 2018 10 312018 10 312018 12 31 17
A.2.1 2018 12 31 2. 10 2018 12 31 3. 2018 12 31 18
4. 2018 12 31 5. 6. 2018 12 31 7. 2018 12 31 2018 12 31 8. 2018 10 31271,802,000 3,645.9 65% (i) 52%1,895.9 19
(ii) 8%291.7 IBI-305 (iii) 4%145.8 IBI-301 (iv) 1%36.5 IBI-303 25%911.5 10%364.5 2018 12 31 398.5 145.0 (i) 121.3 (ii) 10.9IBI-305 (iii) 9.2IBI-301 (iv) 3.6IBI-303 94.3 159.2 20
2018 2017 1 9,477 18,538 93,795 64,406 2 (4,272,090) (42,079) (1,221,687) (611,922) (220,315) (79,490) (136,006) (8,278) (57,187) (68,969) (57,225) (5,872,982) (716,050) (5,771,492) (562,318) (101,490) (153,732) (5,872,982) (716,050) 3 (17.24) (5.96) (17.24) (5.96) 21
22 2018 2017 1,078,053 761,818 52,842 54,090 45,114 60,020 250,307 135,533 1,426,316 1,011,461 66,121 57,722 72,309 53,762 7,505 13,726 13,068 809,484 1,248 1,248 4,525,352 510,471 4,686,261 1,445,755 4 42,821 34,836 600,498 122,540 17,002 900 10,000 5,000 670,321 163,276 4,015,940 1,282,479 5,442,256 2,293,940 449,887 348,765 782,000 505,000 15,955 11,211 4 3,051,092 1,247,842 3,916,068 4,194,414 (1,622,128) 79 8 4,194,335 (1,942,556) 4,194,414 (1,942,548) 320,420 4,194,414 (1,622,128)
20172018 12 31 2018 1 1 20172018 12 312019 1 1 9 16 1 17 3 23 1 3 4 10 2 28 1 5 8 19 1 28 1 20152017 1 1 2019 1 1 2 3 2021 1 1 4 2020 1 1 5 2020 1 1 23
16 16 1617 16 16 17 16 16 1. 2018 2017 10,000 9,477 8,538 9,477 18,538 24
2018 2017 9,477 18,538 10% 2018 2017 A 9,177 18,538 2. 2018 2017 (3,316) 5,141 38,204 (4,338,044) (51,013) 64,129 (29,270) (4,272,090) (42,079) 25
3. (a) 12 31 2018 2017 (5,771,492) (562,318) 334,683,802 94,310,080 2018 12 31 (b) 2018 12 31 2018 12 31 26
4. a) b) A 2011 10 11 2 5,000,000 1 5,000 31,821 B 1 2012 6 21 3 9,090,912 2.2 20,000 126,270 2 2012 11 14 1 2,272,727 2.2 5,000 31,500 3 2013 5 20 * 1 2,272,727 2.2 5,000 31,095 13,636,366 C 1A 2014 12 26 10 13,617,946 7.2375 98,560 604,168 1B 2014 12 26 * 1 198,963 7.2375 1,440 9,032 2 2015 12 17 1 2,072,539 7.2375 15,000 95,367 15,889,448 D 1 2016 9 26 9 15,081,805 12.2 184,000 1,228,374 2 2016 12 23 * 4 6,393,373 12.2 78,002 542,078 21,475,178 E 1 2018 1 31 2 6,706,409 13.42 90,000 570,051 2 2018 4 4 11 4,470,939 13.42 60,000 377,770 11,177,348 * 27
2018 10 31 13.98 www.hkexnews.hk www.innoventbio.com 2018 12 31 2019 3 13 Charles Leland Cooney 28